- Mild to moderately active Ulcerative Colitis (UC)
- Maintenance of remission of Ulcerative Colitis (UC)
- Treatment & maintenance of remission of Crohn’s Disease (CD)
Mesalamine works locally at colonic mucosa of the Gut. It reduces inflammation by inducing activation and expression of PPAR-γ and inhibiting inflammatory mediators (IL-1, TNF, NFkB & Leukotriene, arachidonic acid metabolites, free oxygen radical. It increases immunosuppression by inhibiting antibody production.
It also reduces UC associated Colorectal Cancer (CRC) by inducing anti-tumorigenic effect and apoptosis of the inflamed cells.
Dosage & Administration:
Acute disease: 3-6 delayed release tablets (2400-4800 mg) daily in divided doses for 6 (six) weeks.
Maintenance therapy: The recommended dosage is 3 delayed release tablets (2400 mg) daily in divided doses.
Maintenance of remission of Crohn’s disease: 3 delayed release tablets (2400 mg) daily in divided doses.